Product Name:1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

IUPAC Name:(3-{[(ethylimino)methylidene]amino}propyl)dimethylamine hydrochloride

Molecular Formula:C8H18ClN3
Catalog Number:CM303421
Molecular Weight:191.7

Packing Unit Available Stock Price($) Quantity
CM303421-1000g in stock ƴijŮ

For R&D use only.

Inquiry Form


Product Details

CAS NO:25952-53-8
Molecular Formula:C8H18ClN3
Melting Point:-
Smiles Code:CCN=C=NCCCN(C)C.[H]Cl
Catalog Number:CM303421
Molecular Weight:191.7
Boiling Point:197.7°C at 760 mmHg
MDL No:MFCD00012503
Storage:Keep in a dry and a tight container and store at 2°C~8°C

Column Infos

GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.